专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07632521B2 Controlled release potassium chloride tablets 失效
标题翻译：控释氯化钾片
公开(公告)号：US07632521B2
公开(公告)日：2009-12-15
申请号：US10619924
申请日：2003-07-15
申请人： Gopi Venkatesh , Craig Kramer
发明人： Gopi Venkatesh , Craig Kramer
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/26
CPC分类号： A61K33/14 , A61K9/2081 , A61K9/5073
摘要： A unit dosage form, such as a tablet for delivering potassium into the body in a controlled release fashion, comprises of a multiplicity of microencapsulated potassium chloride crystals, which are further coated with a plasticized polymer to improve compressibility of the microcapsules. The compressible microcapsules are blended with a compression aid, such as microcrystalline cellulose and a glidant, such as colloidal silicon dioxide, to form controlled release potassium chloride tablets. The tablets may optionally include other excipients such as surfactants and disintegrants. The tablets thus produced exhibit not only high crushing strength and low friability but also release potassium in humans in a desired controlled release fashion similar to commercially available potassium chloride tablets.
摘要翻译：单位剂型，例如以控制释放方式将钾输送到体内的片剂，包含多个微胶囊化的氯化钾晶体，其进一步用增塑聚合物涂覆以改善微胶囊的压缩性。可压缩微胶囊与压缩助剂如微晶纤维素和助流剂如胶体二氧化硅混合，形成控制释放的氯化钾片。片剂可以任选地包括其它赋形剂，例如表面活性剂和崩解剂。如此生产的片剂不仅具有高的抗碎强度和低脆性，而且以类似于市售的氯化钾片剂的所需的控制释放方式释放人体中的钾。

2. 发明申请

US20050013860A1 Controlled release potassium chloride tablets 失效
标题翻译：控释氯化钾片
公开(公告)号：US20050013860A1
公开(公告)日：2005-01-20
申请号：US10619924
申请日：2003-07-15
申请人： Gopi Venkatesh , Craig Kramer
发明人： Gopi Venkatesh , Craig Kramer
IPC分类号： A61K9/20 , A61K9/22 , A61K9/26 , A61K9/50 , A61K33/14
CPC分类号： A61K33/14 , A61K9/2081 , A61K9/5073
摘要： In accordance with the present invention, controlled release potassium chloride tablets are prepared from a pharmaceutical composition comprised of potassium chloride particles coated with a membrane of plasticized water swellable/soluble polymer. The coated Potassium chloride particles are blended with pharmaceutical excipients and compressed into tablets.
摘要翻译：根据本发明，控释氯化钾片剂由包覆有增塑水溶胀性/可溶性聚合物膜的氯化钾颗粒组成的药物组合物制备。将涂覆的氯化钾颗粒与药物赋形剂混合并压制成片剂。

3. 发明申请

US20090202630A1 ORALLY DISINTEGRATING TABLET COMPOSITIONS OF RANITIDINE AND METHODS OF MANUFACTURE 审中-公开
标题翻译： ORALYATGITTING RANTETIINE的片剂组合物及其制备方法
公开(公告)号：US20090202630A1
公开(公告)日：2009-08-13
申请号：US12370852
申请日：2009-02-13
申请人： Gopi Venkatesh , Craig Kramer , Julius Dave King, JR. , Bennie L. Young
发明人： Gopi Venkatesh , Craig Kramer , Julius Dave King, JR. , Bennie L. Young
IPC分类号： A61K31/341 , A61K9/50 , A61K9/20
CPC分类号： A61K31/341 , A61K9/0056 , A61K9/1641 , A61K9/1652 , A61K9/5026 , A61K9/5042
摘要： The present invention is directed to pharmaceutical compositions comprising taste-masked microcapsules comprising ranitidine, orally disintegrating tablets comprising such compositions, and methods of making the pharmaceutical compositions and dosage forms of the present invention. The present invention is also directed to methods of administering the pharmaceutical compositions and orally disintegrating tablets to treat or prevent gastrointestinal disorders.
摘要翻译：本发明涉及药物组合物，其包含含有雷尼替丁的口罩微胶囊，包含该组合物的口腔崩解片，以及制备本发明的药物组合物和剂型的方法。本发明还涉及给药药物组合物和口腔崩解片剂治疗或预防胃肠道疾病的方法。

4. 发明授权

US08962022B2 Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family 有权
标题翻译：药物组合物包含取代的二苯甲基哌嗪族的活性物质
公开(公告)号：US08962022B2
公开(公告)日：2015-02-24
申请号：US12057177
申请日：2008-03-27
申请人： Gopi Venkatesh
发明人： Gopi Venkatesh
IPC分类号： A61K9/20 , A61K9/26 , A61K9/24 , A61K31/497 , C07D295/00 , A61K9/00 , A61K9/50
CPC分类号： A61K9/0056 , A61K9/2077 , A61K9/5026 , A61K9/5047 , A61K9/5078
摘要： The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.
摘要翻译：本发明涉及包含取代的二苯甲基哌嗪涂层和包含水不溶性聚合物和胃溶性聚合物的掩味层的掩味微粒的组合物，以及制备这种掩味微粒的方法。本发明还涉及包含取代的二苯甲基哌嗪和快速分散颗粒的掩味微粒的稳定的口腔崩解组合物，以及制备这种口腔崩解组合物的方法。

5. 发明申请

US20140287035A1 PANCREATIC ENZYME COMPOSITIONS AND METHODS FOR TREATING PANCREATITIS AND PANCREATIC INSUFFICIENCY 审中-公开
标题翻译：胰蛋白酶组合物和治疗胰腺癌和胰腺癌的方法
公开(公告)号：US20140287035A1
公开(公告)日：2014-09-25
申请号：US14296832
申请日：2014-06-05
申请人： Stephen Perrett , Ruth Thieroff-Ekerdt , Gopi Venkatesh , Konstantinos Efthymiopoulos
发明人： Stephen Perrett , Ruth Thieroff-Ekerdt , Gopi Venkatesh , Konstantinos Efthymiopoulos
IPC分类号： A61K9/16 , A61K38/48 , A61K38/46
CPC分类号： A61K9/16 , A61K9/2813 , A61K9/2866 , A61K9/4808 , A61K9/5084 , A61K38/00 , A61K38/465 , A61K38/48
摘要： Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.
摘要翻译：包含肠溶包衣和未包被胰酶的珠的组合的本发明的组合物可用于治疗或预防胰腺炎疼痛，以及任选与消化酶缺陷相关的病症。

6. 发明授权

US08133506B2 Drug delivery systems comprising weakly basic drugs and organic acids 有权
标题翻译：包括弱碱性药物和有机酸的药物递送系统
公开(公告)号：US08133506B2
公开(公告)日：2012-03-13
申请号：US12209285
申请日：2008-09-12
申请人： Gopi Venkatesh , Jin-Wang Lai , Nehal H. Vyas , Vivek Purohit
发明人： Gopi Venkatesh , Jin-Wang Lai , Nehal H. Vyas , Vivek Purohit
IPC分类号： A61K9/48 , A61K9/16 , A61K31/4178
CPC分类号： A61K31/4178 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/1676 , A61K9/2081 , A61K9/48 , A61K9/5042 , A61K9/5078 , A61K9/5084
摘要： The present invention is directed to pharmaceutical compositions, and methods of making such compositions, wherein the compositions comprise a plurality of TPR and RR particles, wherein: the TPR particles each comprise a core coated with a TPR layer; the core comprises a weakly basic, poorly soluble drug and a pharmaceutically acceptable organic acid separated from each other by an SR layer; the RR particles each comprise the weakly basic, poorly soluble drug, and release at least about 80 wt. % of the weakly basic, poorly soluble drug in about 5 minutes when dissolution tested using United States Pharmacopoeia (USP) dissolution methodology (Apparatus 2—paddles@50 RPM and a two-stage dissolution medium at 37° C. (first 2 hours in 0.1N HCl followed by testing in a buffer at pH 6.8).
摘要翻译：本发明涉及药物组合物和制备这种组合物的方法，其中组合物包含多个TPR和RR颗粒，其中：TPR颗粒各自包含涂覆有TPR层的芯; 核心包括通过SR层彼此分离的弱碱性，难溶性药物和药学上可接受的有机酸; RR颗粒各自包含弱碱性，难溶性的药物，并且释放至少约80wt。当使用美国药典（USP）溶出方法进行溶出测试时，约5分钟内弱碱性，溶解性差的药物的百分比（装置2-桨叶，50RPM，两步溶解培养基在37℃（前2小时 0.1N HCl，然后在pH 6.8的缓冲液中测试）。

7. 发明授权

US07820203B2 Modified release dosage forms of skeletal muscle relaxants 有权
公开(公告)号：US07820203B2
公开(公告)日：2010-10-26
申请号：US12026882
申请日：2008-02-06
申请人： Gopi Venkatesh , James M. Clevenger
发明人： Gopi Venkatesh , James M. Clevenger
IPC分类号： A61K9/14
CPC分类号： A61K31/135 , A61K9/0053 , A61K9/1652 , A61K9/2054 , A61K9/4808 , A61K9/4866 , A61K9/5078 , A61K31/137 , A61K31/5513 , Y10T29/49826
摘要： A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.

8. 发明申请

US20050232988A1 Orally disintegrating tablets and methods of manufacture 有权
标题翻译：口腔崩解片和制造方法
公开(公告)号：US20050232988A1
公开(公告)日：2005-10-20
申请号：US10827106
申请日：2004-04-19
申请人： Gopi Venkatesh , Ken Qian , Shyam Vangala , James Clevenger , Donald Guenther
发明人： Gopi Venkatesh , Ken Qian , Shyam Vangala , James Clevenger , Donald Guenther
IPC分类号： A61K9/00 , A61K9/16 , A61K9/20 , A61K9/46 , A61K9/50 , A61K31/34
CPC分类号： A61K9/2081 , A61K9/0056 , A61K9/1623 , A61K9/1635 , A61K9/2018 , A61K9/2027 , A61K9/2095 , A61K9/5042 , A61K31/34 , A61K31/341 , A61K31/4045
摘要： A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drug, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.
摘要翻译：一种在口腔内快速崩解的片剂，其包含通过将平均粒度小于约30微米的糖醇或糖或其混合物制成的快速分散微粒的压缩共混物和崩解剂，以及掩味微胶囊含有至少一种药物，所述微胶囊通过将包含至少一种治疗有效量的药物的药学上可接受的制剂和至少一种改善微粒回弹性的聚合物粘合剂制粒，湿法研磨造粒物质，并将研磨的颗粒微胶囊化以提供微胶囊。

9. 发明申请

US20050106247A1 Modified release dosage forms of skeletal muscle relaxants 有权
标题翻译：骨骼肌松弛剂的改性释放剂型
公开(公告)号：US20050106247A1
公开(公告)日：2005-05-19
申请号：US10713929
申请日：2003-11-14
申请人： Gopi Venkatesh , James Clevenger
发明人： Gopi Venkatesh , James Clevenger
IPC分类号： A61K9/50 , A61K31/5513 , A61K9/26
CPC分类号： A61K31/135 , A61K9/0053 , A61K9/1652 , A61K9/2054 , A61K9/4808 , A61K9/4866 , A61K9/5078 , A61K31/137 , A61K31/5513 , Y10T29/49826
摘要： A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
摘要翻译：用于以延长或持续释放的方式将骨骼肌松弛剂（例如盐酸环苯扎林）输送到体内的单位剂型，包括一种或多种含药颗粒群（珠粒，丸粒，颗粒等）。至少一个珠粒表现出预先设计的持续释放特征。这种药物递送系统设计为每日一次口服给药以维持足够的血浆浓度 - 时间特征，从而在24小时内缓解与疼痛的肌肉骨骼病症相关的肌肉痉挛。

10. 发明申请

US20050025824A1 Pulsatile release histamine H2 antagonist dosage form 审中-公开
标题翻译：脉冲释放组胺H2拮抗剂剂型
公开(公告)号：US20050025824A1
公开(公告)日：2005-02-03
申请号：US10875627
申请日：2004-06-25
申请人： Phillip Percel , Nehal Vyas , Krishna Vishnupad , Gopi Venkatesh
发明人： Phillip Percel , Nehal Vyas , Krishna Vishnupad , Gopi Venkatesh
IPC分类号： A61K9/50 , A61K9/52 , A61K9/20
CPC分类号： A61K9/5084 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5078
摘要： A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
摘要翻译：公开了一种用于以包含一种或多种含药颗粒（珠粒，丸粒，颗粒等）群体的昼夜释放方式将药物输送到体内的单位剂型，例如胶囊等。每个珠粒表现出具有或不具有3至5小时的预定滞后时间的预设计的快速或持续释放曲线。这种昼夜节律释放药物递送系统被设计为提供血浆浓度 - 时间曲线，其在给药期间的不同时间根据生理需要而变化，即模拟昼夜节律和胃酸分泌的严重性/表现（和/ 或午夜g d），基于药物动力学和药物动力学考虑以及体外/体内相关性预测。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式